Show simple item record

dc.contributor.authorMurphy, Nick
dc.contributor.authorLynch, Kevin
dc.contributor.authorLohan, Paul
dc.contributor.authorTreacy, Oliver
dc.contributor.authorRitter, Thomas
dc.date.accessioned2017-03-27T11:10:13Z
dc.date.issued2016-12
dc.identifier.citationMurphy, Nick, Lynch, Kevin, Lohan, Paul, Treacy, Oliver, & Ritter, Thomas. (2016). Mesenchymal stem cell therapy to promote corneal allograft survival: current status and pathway to clinical translation. Current Opinion in Organ Transplantation, 21(6), 559-567. doi: 10.1097/mot.0000000000000360en_IE
dc.identifier.issn1531-7013
dc.identifier.urihttp://hdl.handle.net/10379/6410
dc.description.abstractPURPOSE OF REVIEW: This article reviews the literature on the therapeutic potential of mesenchymal stem cells (MSCs) to prolong corneal allograft survival. RECENT FINDINGS: To date, only small numbers studies have investigated the MSC ability to modulate corneal allograft survival. Most reports have shown positive results, which is encouraging, however as different MSC-application strategies (time point of injection, cell number/number of injections, route of injection, MSC source, MSC licensing) have been employed in various animal models it is difficult to compare and validate the results. The MSC ability to promote graft survival has been attributed to their modulation of the recipient immune system, altering the Th1/Th2 balance, expanding Foxp3 regulatory T cells, polarizing macrophages and inhibiting intra-graft infiltration of antigen presenting cells. More in depth analysis is required to elucidate the mechanism of MSC-immunomodulation in vivo. SUMMARY: MSCs have shown the potential to modulate corneal allograft rejection in various models using MSCs from different species. In particular for high-risk patients with poor prognosis MSC therapy might be a promising approach to promote corneal allograft survival. First-in-man clinical trials with MSC will hopefully shed new light on MSC-mediated immunomodulation in vivo and contribute to the restoration of vision in patients receiving corneal allografts.en_IE
dc.description.sponsorshipThis work is supported by Science Foundation Ireland (12/IA/1624) and by a grant from the European Commission [FP7 Collaborative Health Project VISICORT (grant number 602470), www.visicort.eu] and by infrastructural funds from the European Regional Development Fund.en_IE
dc.formatapplication/pdfen_IE
dc.language.isoenen_IE
dc.publisherLippincott, Williams & Wilkinsen_IE
dc.relation.ispartofCurrent Opinion In Organ Transplantationen
dc.subjectCorneal transplantationen_IE
dc.subjectImmunomodulationen_IE
dc.subjectMesenchymal stem cellsen_IE
dc.subjectRegulatory cellsen_IE
dc.subjectToleranceen_IE
dc.subjectMedicineen_IE
dc.titleMesenchymal stem cell therapy to promote corneal allograft survival: current status and pathway to clinical translationen_IE
dc.typeArticleen_IE
dc.date.updated2017-03-27T10:55:34Z
dc.identifier.doi10.1097/MOT.0000000000000360
dc.local.publishedsourcehttp://dx.doi.org/10.1097/MOT.0000000000000360en_IE
dc.description.peer-reviewedpeer-reviewed
dc.contributor.funder|~|1267872|~|1267883|~|
dc.description.embargo2017-12-31
dc.internal.rssid12279964
dc.local.contactThomas Ritter, School Of Medicine, Regenerative Medicine Institute, Biosciences, Dangan. 5329 Email: thomas.ritter@nuigalway.ie
dc.local.copyrightcheckedNo
dc.local.versionACCEPTED
nui.item.downloads205


Files in this item

Attribution-NonCommercial-NoDerivs 3.0 Ireland
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. Please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.

The following license files are associated with this item:

Thumbnail

This item appears in the following Collection(s)

Show simple item record